Will the results be positive?
The intrinsic forecast suggests a 45% chance of a positive outcome, but the market price for YES is 0.49875396, which implies a slightly higher market expectation. Given the portfolio has $12286.283 in cash and the...
The market price of ~$0.50 is an accurate reflection of the uncertainty. The intrinsic probability of a clearly positive outcome is lower, but the market is correctly priced for the risk.
Intrinsic forecast (35% YES) is below market price (~49.9% YES), creating a pricing gap. BUY_NO offers value, purchasing the undervalued NO side. Using full maxBuyUsd within cash constraints.
At ~50%, the market drastically underestimates the probability of success. The primary MTD/RP2D endpoint was already met for monotherapy (ASCO 2023), and a 2025 ADME study confirms Pfizer's continued development.
Intrinsic 70% YES vs market 50% implies 40% edge. No position, ample cash, max buy feasible. Strong safety trial odds undervalued near fair.
